Website Notice Block

Press Releases

Date Title and Summary View
Toggle Summary MediWound Appoints Mr. Boaz Gur-Lavie as Chief Financial Officer
YAVNE, Israel , June 11, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced the appointment of Mr.
View HTML
Toggle Summary NexoBrid® Receives Marketing Authorization from Peru’s Ministry of Health
Avalon Pharmaceutical Peru S.A.C., MediWound’s exclusive distributor, plans commercial launch for first half of 2020 YAVNE, Israel , June 04, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in
View HTML
Toggle Summary BARDA Upsizes Support for NexoBrid with an Additional $21 Million to Fund Continuous Access Treatment Protocol for Thermal Burn
Total non-dilutive funds for NexoBrid now valued at up to $196 Million MediWound to initiate NexoBrid expanded access treatment protocol (NEXT) in the third quarter of 2019, allowing for ongoing use of NexoBrid to treat burn patients in U.S. YAVNE, Israel , May 29, 2019 (GLOBE NEWSWIRE) --
View HTML
Toggle Summary MediWound Reports First Quarter 2019 Financial Results
Met Primary and All Secondary Endpoints in Pivotal Phase 3 DETECT Study; NexoBrid BLA Filing Planned for Fourth Quarter of 2019 Signed Exclusive License Agreement with Vericel for Commercial Rights to NexoBrid ® in North America Conference call begins today at 8:30 a.m.
View HTML
Toggle Summary MediWound to Host First Quarter Financial Results Conference Call on May 21at 8:30 a.m. Eastern Time
YAVNE, Israel , May 14, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the first
View HTML
Toggle Summary MediWound Enters into Exclusive License Agreement with Vericel for Commercial Rights to NexoBrid® in North America
$17.5 million upfront, sales royalties and up to $132.5 million in potential milestones Leverages Vericel’s Commercial Capabilities and Presence in U.S. Burn Care Market Biologics License Application (BLA) Filing Planned for Fourth Quarter of 2019 Company to Host a Conference Call Today at 8:00 am
View HTML
Toggle Summary MediWound Files Annual Report on Form 20-F for the Year Ended December 31, 2018
YAVNE, Israel , March 26, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD ), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that it has filed its annual report on Form 20-F for the fiscal
View HTML
Toggle Summary MediWound Reports Fourth Quarter and Fiscal Year 2018 Financial Results
Met Primary and All Secondary Endpoints in its Pivotal Phase 3 Study (DETECT) in NexoBrid ® for Eschar Removal of Severe Thermal Burns Awarded Additional BARDA Contract Valued up to $43 Million for the Development of NexoBrid for Sulfur Mustard Injuries Conference call begins today at 8:30 a.m.
View HTML
Toggle Summary MediWound to Host Fourth Quarter & Fiscal 2018 Financial Results Conference Call on March 25 at 8:30 a.m. Eastern Time
YAVNE, Israel , March 18, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the fourth
View HTML
Toggle Summary MediWound Announces Executive Leadership Changes
Chief Executive Officer Gal Cohen stepping down  Available for transition and ongoing strategic process support  Chief Financial & Operations Officer Sharon Malka will be appointed CEO   Chairmen of the Board Stephen T. Wills will serve as Active Chairman YAVNE, Israel , March 12, 2019 (GLOBE
View HTML